

Neil Fleshner

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9688366/publications.pdf>

Version: 2024-02-01

102
papers

2,556
citations

257101

24
h-index

205818

48
g-index

104
all docs

104
docs citations

104
times ranked

4022
citing authors

#	ARTICLE	IF	CITATIONS
1	Spatial genomic heterogeneity within localized, multifocal prostate cancer. <i>Nature Genetics</i> , 2015, 47, 736-745.	9.4	395
2	Metformin Use and All-Cause and Prostate Cancer-Specific Mortality Among Men With Diabetes. <i>Journal of Clinical Oncology</i> , 2013, 31, 3069-3075.	0.8	240
3	Epidemiology and Prevention of Prostate Cancer. <i>European Urology Oncology</i> , 2021, 4, 877-892.	2.6	190
4	A Prostate Cancer "Nimbus" Genomic Instability and SCHLAP1 Dysregulation Underpin Aggression of Intraductal and Cribriform Subpathologies. <i>European Urology</i> , 2017, 72, 665-674.	0.9	142
5	Role of "saturation biopsy" in the detection of prostate cancer among difficult diagnostic cases. <i>Urology</i> , 2002, 60, 93-97.	0.5	115
6	Active Surveillance Magnetic Resonance Imaging Study (ASIST): Results of a Randomized Multicenter Prospective Trial. <i>European Urology</i> , 2019, 75, 300-309.	0.9	99
7	Randomized Study of Systematic Biopsy Versus Magnetic Resonance Imaging and Targeted and Systematic Biopsy in Men on Active Surveillance (ASIST): 2-year Postbiopsy Follow-up. <i>European Urology</i> , 2020, 77, 311-317.	0.9	99
8	Dietary Fat and Prostate Cancer. <i>Journal of Urology</i> , 2004, 171, S19-24.	0.2	83
9	Delay in the progression of low-risk prostate cancer: Rationale and design of the Reduction by Dutasteride of Clinical Progression Events in Expectant Management (REDEEM) trial. <i>Contemporary Clinical Trials</i> , 2007, 28, 763-769.	0.8	67
10	EVIDENCE FOR CONTAMINATION OF HERBAL ERECTILE DYSFUNCTION PRODUCTS WITH PHOSPHODIESTERASE TYPE 5 INHIBITORS. <i>Journal of Urology</i> , 2005, 174, 636-641.	0.2	64
11	Prostate cancer prevention. <i>Cancer</i> , 2007, 110, 1889-1899.	2.0	60
12	Prevalence of Inflammation and Benign Prostatic Hyperplasia on Autopsy in Asian and Caucasian Men. <i>European Urology</i> , 2014, 66, 619-622.	0.9	57
13	Recommendations for the improvement of bladder cancer quality of care in Canada: A consensus document reviewed and endorsed by Bladder Cancer Canada (BCC), Canadian Urologic Oncology Group (CUOG), and Canadian Urological Association (CUA), December 2015. <i>Canadian Urological Association Journal</i> , 2016, 10, 46.	0.3	55
14	Application of a Clinical Whole-Transcriptome Assay for Staging and Prognosis of Prostate Cancer Diagnosed in Needle Core Biopsy Specimens. <i>Journal of Molecular Diagnostics</i> , 2016, 18, 395-406.	1.2	46
15	Growth kinetics of small renal masses: A prospective analysis from the Renal Cell Carcinoma Consortium of Canada. <i>Canadian Urological Association Journal</i> , 2014, 8, 24.	0.3	44
16	Concordance of biopsy and prostatectomy diagnosis of intraductal and cribriform carcinoma in a prospectively collected data set. <i>Histopathology</i> , 2019, 74, 474-482.	1.6	44
17	Comparison of Magnetic Resonance Imaging and Transrectal Ultrasound Informed Prostate Biopsy for Prostate Cancer Diagnosis in Biopsy Naïve Men: A Systematic Review and Meta-Analysis. <i>Journal of Urology</i> , 2020, 203, 1085-1093.	0.2	44
18	Quantitative DNA methylation analysis of genes coding for kallikrein-related peptidases 6 and 10 as biomarkers for prostate cancer. <i>Epigenetics</i> , 2012, 7, 1037-1045.	1.3	42

#	ARTICLE	IF	CITATIONS
19	Novel Multiplex MethyLight Protocol for Detection of DNA Methylation in Patient Tissues and Bodily Fluids. <i>Scientific Reports</i> , 2015, 4, 4432.	1.6	38
20	Avoiding Unnecessary Biopsy: MRI-based Risk Models versus a PI-RADS and PSA Density Strategy for Clinically Significant Prostate Cancer. <i>Radiology</i> , 2021, 300, 369-379.	3.6	34
21	A Systematic Review and Network Meta-analysis of Novel Androgen Receptor Inhibitors in Non-metastatic Castration-resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 343-350.	0.9	33
22	Quality indicators in the management of bladder cancer: A modified Delphi study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 328-334.	0.8	29
23	A urine-based DNA methylation assay, ProCUrE, to identify clinically significant prostate cancer. <i>Clinical Epigenetics</i> , 2018, 10, 147.	1.8	26
24	Advanced Androgen Blockage in Nonmetastatic Castration-resistant Prostate Cancer: An Indirect Comparison of Apalutamide and Enzalutamide. <i>European Urology Oncology</i> , 2018, 1, 238-241.	2.6	25
25	Expression of Small Noncoding RNAs in Urinary Exosomes Classifies Prostate Cancer into Indolent and Aggressive Disease. <i>Journal of Urology</i> , 2020, 204, 466-475.	0.2	24
26	Development and external validation of a biopsy-derived nomogram to predict risk of ipsilateral extraprostatic extension. <i>BJU International</i> , 2017, 120, 76-82.	1.3	23
27	Defining a Cohort that May Not Require Repeat Prostate Biopsy Based on PCA3 Score and Magnetic Resonance Imaging: The Dual Negative Effect. <i>Journal of Urology</i> , 2018, 199, 1182-1187.	0.2	22
28	Stricter Active Surveillance Criteria for Prostate Cancer do Not Result in Significantly Better Outcomes: A Comparison of Contemporary Protocols. <i>Journal of Urology</i> , 2016, 196, 1645-1650.	0.2	19
29	Distinct DNA methylation alterations are associated with cribriform architecture and intraductal carcinoma in Gleason pattern 4 prostate tumors. <i>Oncology Letters</i> , 2017, 14, 390-396.	0.8	19
30	Germ Cell Testicular Tumors—Contemporary Diagnosis, Staging and Management of Localized and Advanced disease. <i>Urology</i> , 2019, 125, 8-19.	0.5	19
31	Examining the ability of the Cancer and Aging Research Group tool to predict toxicity in older men receiving chemotherapy or androgen-receptor-targeted therapy for metastatic castration-resistant prostate cancer. <i>Cancer</i> , 2021, 127, 2587-2594.	2.0	16
32	Metabolic heterogeneity signature of primary treatment-naïve prostate cancer. <i>Oncotarget</i> , 2017, 8, 25928-25941.	0.8	16
33	First experiences with Lu-177 PSMA therapy in combination with Pembrolizumab or after pretreatment with Olaparib in single patients. <i>Journal of Nuclear Medicine</i> , 2021, 62, jnumed.120.249029.	2.8	15
34	Psychological distress associated with active surveillance in patients younger than 70 with a small renal mass. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 603.e17-603.e25.	0.8	14
35	Active surveillance in patients with a PSA \geq 10 ng/mL. <i>Canadian Urological Association Journal</i> , 2014, 8, 702.	0.3	12
36	The Suggested Unique Association Between the Various Statin Subgroups and Prostate Cancer. <i>European Urology Focus</i> , 2021, 7, 537-545.	1.6	12

#	ARTICLE	IF	CITATIONS
37	Utility of digital rectal examination in a population with prostate cancer treated with active surveillance. <i>Canadian Urological Association Journal</i> , 2020, 14, E453-E457.	0.3	11
38	Association of Chemotherapy, Enzalutamide, Abiraterone, and Radium 223 With Cognitive Function in Older Men With Metastatic Castration-Resistant Prostate Cancer. <i>JAMA Network Open</i> , 2021, 4, e2114694.	2.8	11
39	Lynch Syndrome in Urologic Malignancies – What Does the Urologist Need to Know?. <i>Urology</i> , 2019, 134, 24-31.	0.5	10
40	Gender-based psychological and physical distress differences in patients diagnosed with non-metastatic renal cell carcinoma. <i>World Journal of Urology</i> , 2020, 38, 2547-2554.	1.2	10
41	An Increase in Gleason 6 Tumor Volume While on Active Surveillance Portends a Greater Risk of Grade Reclassification with Further Followup. <i>Journal of Urology</i> , 2016, 195, 307-312.	0.2	9
42	Improving patient journey and quality of care: Summary from the second Bladder Cancer Canada-Canadian Urological Association- Canadian Urologic Oncology Group (BCC-CUA-CUOG) bladder cancer quality of care consensus meeting. <i>Canadian Urological Association Journal</i> , 2018, 12, E281-97.	0.3	9
43	GBX2 Methylation Is a Novel Prognostic Biomarker and Improves Prediction of Biochemical Recurrence Among Patients with Prostate Cancer Negative for Intraductal Carcinoma and Cribriform Architecture. <i>European Urology Oncology</i> , 2019, 2, 231-238.	2.6	9
44	An integrative DNA methylation model for improved prognostication of postsurgery recurrence and therapy in prostate cancer patients. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 39.e1-39.e9.	0.8	9
45	Optimizing screening and management of cardiovascular health in prostate cancer. <i>Canadian Urological Association Journal</i> , 2020, 14, E458-E464.	0.3	9
46	Target Heterogeneity in Oncology: The Best Predictor for Differential Response to Radioligand Therapy in Neuroendocrine Tumors and Prostate Cancer. <i>Cancers</i> , 2021, 13, 3607.	1.7	9
47	Does the Visibility of Grade Group 1 Prostate Cancer on Baseline Multiparametric Magnetic Resonance Imaging Impact Clinical Outcomes?. <i>Journal of Urology</i> , 2020, 204, 1187-1194.	0.2	9
48	A narrative review of pelvic lymph node dissection in prostate cancer. <i>Translational Andrology and Urology</i> , 2020, 9, 3049-3055.	0.6	9
49	Controversies in the management of testicular seminoma. <i>Urologic Oncology</i> , 2002, 20, 227-233.	1.5	8
50	Negative Predictive Value of Prostate Multiparametric Magnetic Resonance Imaging among Men with Negative Prostate Biopsy and Elevated Prostate Specific Antigen: A Clinical Outcome Retrospective Cohort Study. <i>Journal of Urology</i> , 2019, 202, 1159-1165.	0.2	8
51	Testosterone Breakthrough Rates during Androgen Deprivation Therapy for Castration Sensitive Prostate Cancer. <i>Journal of Urology</i> , 2020, 204, 416-426.	0.2	8
52	Surgical wait times for patients with urological cancers: a survey of Canadian surgeons. <i>Canadian Journal of Urology</i> , 2006, 13 Suppl 3, 3-13.	0.0	8
53	Prostate biopsy in the era of MRI-targeting: towards a judicious use of additional systematic biopsy. <i>European Radiology</i> , 2022, 32, 7544-7554.	2.3	8
54	Understanding how prostate cancer patients value the current treatment options for metastatic castration resistant prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 240.e13-240.e20.	0.8	7

#	ARTICLE	IF	CITATIONS
55	Extraprostatic Extension in Core Biopsies Epitomizes High-risk but Locally Treatable Prostate Cancer. <i>European Urology Oncology</i> , 2019, 2, 88-96.	2.6	7
56	Does Time Spent on Active Surveillance Adversely Affect the Pathological and Oncologic Outcomes in Patients Undergoing Delayed Radical Prostatectomy?. <i>Journal of Urology</i> , 2020, 204, 476-482.	0.2	7
57	Regular Transition Zone Biopsy during Active Surveillance for Prostate Cancer May Improve Detection of Pathological Progression. <i>Journal of Urology</i> , 2014, 192, 1088-1093.	0.2	6
58	The association of male pattern baldness and risk of cancer and high-grade disease among men presenting for prostate biopsy. <i>Canadian Urological Association Journal</i> , 2016, 10, 424.	0.3	6
59	The deleterious association between proton pump inhibitors and prostate cancer-specific mortality â€“ a population-based cohort study. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 622-629.	2.0	6
60	Time from first detectable PSA following radical prostatectomy to biochemical recurrence: A competing risk analysis. <i>Canadian Urological Association Journal</i> , 2015, 9, 14.	0.3	5
61	Switching from a GnRH agonist to a GnRH antagonist in prostate cancer patients: A systematic review and meta-analysis. <i>Canadian Urological Association Journal</i> , 2019, 14, 36-41.	0.3	5
62	Age Differences in Patient-reported Psychological and Physical Distress Symptoms in Bladder Cancer Patients â€“ A Cross Sectional Study. <i>Urology</i> , 2019, 134, 154-162.	0.5	5
63	A Clinical Trial of Prophylactic Prostatectomy for BRCA2 Mutation Carriers: Is Now the Time?. <i>European Urology Focus</i> , 2021, 7, 506-507.	1.6	5
64	A Population-based Study Comparing Outcomes for Patients With Metastatic Castrate Resistant Prostate Cancer Treated by Urologists or Medical Oncologists With First Line Abiraterone Acetate or Enzalutamide. <i>Urology</i> , 2021, 153, 147-155.	0.5	5
65	Defining high-risk prostate cancer: current status. <i>Canadian Journal of Urology</i> , 2005, 12 Suppl 1, 14-7; discussion 94-6.	0.0	5
66	The evolving role of germline genetic testing and management in prostate cancer: Report from the Princess Margaret Cancer Centre International Retreat. <i>Canadian Urological Association Journal</i> , 2021, 15, E623-E629.	0.3	4
67	The role of metformin, statins and diet in men on active surveillance for prostate cancer. <i>World Journal of Urology</i> , 2022, 40, 61-69.	1.2	4
68	Prevalence of adverse pathology features in grade group 2 prostatectomy specimens with synâ€“or metachronous metastatic disease. <i>Prostate</i> , 2022, 82, 345-351.	1.2	4
69	Continuing towards optimization of bladder cancer care in Canada: Summary of the 3rd BCC-CUA-CUOG bladder cancer quality of care consensus meeting. <i>Canadian Urological Association Journal</i> , 2019, 14, E115-E125.	0.3	3
70	Analysis of a practical surgical skills laboratory for nerve sparing radical prostatectomy. <i>World Journal of Urology</i> , 2019, 37, 799-804.	1.2	3
71	Salvage lymph node dissection for prostate-specific membrane antigen (PSMA) positron emission tomography (PET)-identified oligometastatic disease. <i>Canadian Urological Association Journal</i> , 2021, 15, E545-E552.	0.3	3
72	Trimodal therapy vs. radical cystectomy for muscle-invasive bladder cancer: A Markov microsimulation model. <i>Canadian Urological Association Journal</i> , 2021, 16, .	0.3	3

#	ARTICLE	IF	CITATIONS
73	Combining CAPRA-S With Tumor IDC/C Features Improves the Prognostication of Biochemical Recurrence in Prostate Cancer Patients. <i>Clinical Genitourinary Cancer</i> , 2022, 20, e217-e226.	0.9	3
74	Clinical Management of Prostate Cancer in High-Risk Genetic Mutation Carriers. <i>Cancers</i> , 2022, 14, 1004.	1.7	3
75	Is pathology necessary to predict mortality among men with prostate-cancer?. <i>BMC Medical Informatics and Decision Making</i> , 2014, 14, 114.	1.5	2
76	Evaluation of an Aggressive Prostate Biopsy Strategy in Men Younger than 50 Years. <i>Journal of Urology</i> , 2018, 200, 1056-1061.	0.2	2
77	Defining oligometastatic hormone sensitive prostate cancer and clinically significant outcomes: Implications on clinical trials?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 431.e1-431.e8.	0.8	2
78	Novel androgen receptor inhibitors in nonmetastatic castration-resistant prostate cancer: A network meta-analysis.. <i>Journal of Clinical Oncology</i> , 2020, 38, 131-131.	0.8	2
79	Have we mis-PRONOUNCED the cardiovascular risk of GnRH agonists? A critical appraisal of the PRONOUNCE trial. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 657-658.	2.0	2
80	Prostate cancer: chemoprevention update 2005. <i>Canadian Journal of Urology</i> , 2005, 12 Suppl 2, 2-4.	0.0	2
81	Factors Associated with Stent Change and Prognosis in Patients with Malignant Ureteral Obstruction. <i>Journal of Endourology</i> , 2022, 36, 1083-1090.	1.1	2
82	Multidimensional protein identification technology analysis highlights mitoxantrone-induced expression modulations in the primary prostate cancer cell proteome. <i>Proteomics - Clinical Applications</i> , 2009, 3, 347-358.	0.8	1
83	Is there ageism in prostate cancer detection?. <i>Canadian Urological Association Journal</i> , 2013, 3, 211.	0.3	1
84	Salvage HIFU for biopsy confirmed local prostate cancer recurrence after radical prostatectomy and radiation therapy: Case report and literature review. <i>Canadian Urological Association Journal</i> , 2015, 9, 671.	0.3	1
85	Salvage Radiotherapy Following Partial Gland Ablation for Prostate Cancer: Functional and Oncological Outcomes. <i>European Urology Open Science</i> , 2020, 21, 1-4.	0.2	1
86	Primary analysis of a phase II study of metastasis-directed ablative therapy to PSMA (¹⁸F-DCFPyL) PET-MR/CT defined oligorecurrent prostate cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, 5553-5553.	0.8	1
87	Editorial Comment. <i>Journal of Urology</i> , 2019, 202, 504-505.	0.2	1
88	Re: Jeremy Yuen-Chun Teoh, Daniele Castellani, Claudia Mercader, et al. A Quantitative Analysis Investigating the Prevalence of "Manels" in Major Urology Meetings. <i>Euro Urol</i> 2021;80:442-9. <i>European Urology</i> , 2021, 81, e51-e51.	0.9	1
89	Major role for 5-alpha reductase inhibitors in the aging male. <i>Canadian Urological Association Journal</i> , 2007, 1, 22.	0.3	0
90	Are there differences between de novo and secondary upper tract urothelial carcinoma tumours?. <i>Canadian Urological Association Journal</i> , 2019, 13, E292-E299.	0.3	0

#	ARTICLE	IF	CITATIONS
91	The suggested chemopreventive association of metformin with prostate cancer in diabetic patients. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 191.e17-191.e24.	0.8	0
92	Biorepositories and Databanks for the Development of Novel Biomarkers for Genitourinary Cancer Prevention and Management. European Urology Focus, 2021, 7, 513-521.	1.6	0
93	AUTHOR REPLY. Urology, 2021, 153, 155.	0.5	0
94	Outcomes of 200 Patients with Localized Prostate Cancer Enrolled in a Watchful Waiting Protocol. UroOncology, 2002, 2, 93-94.	0.1	0
95	High-dose oral vitamin D3 administration increases serum and prostate levels of vitamin D metabolites safely in prostate cancer patients. FASEB Journal, 2012, 26, 388.5.	0.2	0
96	Reply by Authors. Journal of Urology, 2019, 202, 1165-1165.	0.2	0
97	Reply by Authors. Journal of Urology, 2020, 203, 1093-1093.	0.2	0
98	Reply by Authors. Journal of Urology, 2020, 204, 1194-1194.	0.2	0
99	Reply by Authors. Journal of Urology, 2020, 204, 475-475.	0.2	0
100	The association of statin subgroups with lower urinary tract symptoms following a prostate biopsy. Canadian Urological Association Journal, 2021, 16, .	0.3	0
101	Variability in testosterone measurement between radioimmunoassay (RIA), chemiluminescence assay (CLIA) and liquid chromatography-tandem mass spectrometry (MS) among prostate cancer patients on androgen deprivation therapy (ADT). Urologic Oncology: Seminars and Original Investigations, 2022, , .	0.8	0
102	Salvage partial gland ablation for recurrent prostate cancer following primary partial gland ablation: Functional and oncological outcomes. Urologic Oncology: Seminars and Original Investigations, 2022, , .	0.8	0